Law360 | Fed. Circ. Ruling Clears Judge to OK Mylan's Lialda Generic

Alston & Bird client Mylan Pharmaceuticals Inc. won a significant patent ruling against Shire Development LLC when a Florida federal judge vacated her earlier decision on reconsideration and found that Mylan’s proposed generic version of Shire’s gastrointestinal drug Lialda does not infringe U.S. Patent Number 6,773,720.

Alston & Bird is noted for representing Mylan Pharmaceuticals Inc. in a drug patent dispute with Shire Development LLC.